

This research has been published, in part, in JBC 1998 Apr 10; 272(15): 8910–15.

#### **Methods of Stimulating Proliferation and Differentiation of Human Pancreatic Cells Ex Vivo**

*JS Rubin (NCI), A Hayek, GM Beattie, T Otonkoski, V Quaranta*

Serial Nos. 08/732,230 filed 14 Apr 1997; U.S. Patent 5,888,705 issued 30 Mar 1999; PCT/US9/05521 filed 28 Apr 1995, and 08/235,394 filed 29 Apr 1994; U.S. Patent 5,857,309 issued 24 Dec 1996

These patents and applications generally relate to methods which may be used in treating diabetes. In particular, they describe methods for culturing pancreatic islet cells which will later be transplanted into patients. The culture of the pancreatic islet cells is carried out in the presence of hepatocyte growth factor/scatter factor (HGF/SF) under conditions such that differentiation and/or proliferation of the pancreatic islet cells occurs and insulin production is stimulated or increased. These insulin-producing pancreatic islet cells can then be transplanted into patients having diabetes mellitus (Type I diabetes).

This work has also been published in Otonkoski T et al. Diabetes 43(7): 947–53 (Jul 1994), Hayek A et al. Diabetes 44(12): 1458–60 (Dec 1995), Otonkoski T et al. Endocrinology 137(7): 3131–9 (Jul 1996), and Beattie, GM et al. Diabetes 45(9): 1223–8 (Sep 1996).

Date: August 3, 1999.

#### **Jack Spiegel,**

*Director, Division of Technology Development and Transfer Office of Technology Transfer National Institutes of Health.*

[FR Doc. 99–20458 Filed 8–6–99; 8:45 am]

BILLING CODE 4140–01–P 5

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Environmental Health Sciences; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings:

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Environmental Health Sciences Special Emphasis Panel R13 Review Mtg.

*Date:* August 10, 1999.

*Time:* 1:00 pm to 3:00 pm.

*Agenda:* To review and evaluate grant applications.

*Place:* NIEHS, 79 T. W. Alexander Drive, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709, (Telephone Conference Call).

*Contact Person:* J. Patrick Mastin, Scientific Review Administrator, NIEHS, P.O. Box 12233 MD EC–24, Research Triangle Park, NC 27709, (919) 541–1446.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* National Institute of Environmental Health Sciences Special Emphasis Panel Contract Review on Pathology Support.

*Date:* August 12, 1999.

*Time:* 1:00 pm to 5:00 pm.

*Agenda:* To review and evaluate contract proposals.

*Place:* NIEHS, 79 T. W. Alexander Drive, Building 4401, Conference Room 3446, Research Triangle Park, NC 27709, (Telephone Conference Call).

*Contact Person:* David Brown, Scientific Review Administrator, Nat'l Institute of Environmental Health Sciences, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541–4964.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences, National Institute of Health, HHS).

Dated: August 3, 1999.

#### **Anna Snouffer,**

*Acting Committee Management Officer, NIH.*

[FR Doc. 99–20459 Filed 8–6–99; 8:45 am]

BILLING CODE 4140–01–M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute on Aging; Notice of Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Aging.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council on Aging.

*Date:* September 23–24, 1999.

*Open:* September 23, 1999, 1:00 p.m. to 5:30 p.m.

*Agenda:* Call to Order; Report of Review of NIA Minority Research Program; Program Highlights and Presentation on Perspectives on Minority Aging.

*Place:* National Institutes of Health, Shannon Building, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.

*Open:* September 24, 1999, 8:00 a.m. to 10:15 a.m.

*Agenda:* Report on Working Group on Program and Discussion on NIA Strategic Plan.

*Place:* National Institutes of Health, Shannon Building, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.

*Closed:* September 24, 1999, 10:30 a.m. to Adjournment.

*Agenda:* To review and evaluate review of Applications.

*Place:* National Institutes of Health, Shannon Building, Wilson Hall, 1 Center Drive, Bethesda, MD 20892.

*Contact Person:* Miriam F. Kelty, Director, Office of Extramural Affairs, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Suite 2C218, Bethesda, MD 20892, 301–496–9322. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: August 3, 1999.

**Anna Snouffer,**

*Acting, Committee Management Officer, NIH.*

[FR Doc. 99-20460 Filed 8-6-99; 8:45 am]

BILLING CODE 4140-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive License: Vaccine to Treat and Prevent Disease Caused by Human Papillomaviruses, Particularly Cervical Cancer

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a exclusive license worldwide to practice the invention embodied in: PCT Patent Application Number PCT/US97/12115 (NIH Reference Number E-032-96/1), entitled "Infectious Papillomavirus Pseudoviral Particles", filed July 14, 1997, to American Home Products Corporation through its Wyeth-Ayerst Laboratories Division, Wyeth-Lederle Vaccines business unit, having a place of business in Madison, N.J. The patent right in this invention has been assigned to the United States of America.

**DATES:** Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 8, 1999 will be considered.

**ADDRESSES:** Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Robert Benson, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 267; Facsimile: (301) 402-0220, e mail: rb20m@nih.gov..

**SUPPLEMENTARY INFORMATION:** The patent application describes pseudoviral particles of papillomavirus capsids encapsidating DNA useful for gene therapy and as vaccines. The pseudoviral particles are made by co-expressing the papillomavirus L1, L2 and E2 genes in a cell line along with a vector comprising the useful DNA and DNA containing E2 protein binding sites (E2BS). The presence of the E2BS containing DNA results in the

encapsidation of the DNA. The encapsidated DNA can be a gene to replace a defective gene, or can encode an antigen, for gene therapy or immunization respectively. Since papillomaviruses selectively multiply in epithelial cells, the capsids may be particularly useful for mucosal vaccines, and for delivering genes to epithelial tissues. The existence of many non-crossreacting serotypes of human and other animal papillomaviruses can be taken advantage of to eliminate the problem of immune rejection upon the second injection of a pseudoviral particle. The same gene or antigen encoding DNA can be incorporated in pseudoviral particles of different serotypes for multiple dosing.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the development of vaccines for the prevention or treatment of diseases in humans caused by infection with human papillomaviruses.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Date: August 3, 1999

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 99-20457 Filed 8-6-99; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4441-N-44]

#### Submission for OMB Review: HMDA Loan/Application Register

**AGENCY:** Office of the Assistant Secretary for Administration, HUD.

**ACTION:** Notice.

**SUMMARY:** This report collects information for mortgage lenders on application for, and originations and purchases of, mortgage and home

improvement loans. Non-depository mortgage lending institutions are required to use the report as a running log throughout the calendar year and send it to HUD by March 1 of the following calendar year.

**DATES:** *Comments Due Date:* September 8, 1999.

**ADDRESSES:** Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.

**FOR FURTHER INFORMATION CONTACT:** Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, Southwest, Washington, DC 20410, telephone (202) 708-2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.

**SUPPLEMENTARY INFORMATION:** The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hour of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the names and telephone numbers of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

**Authority:** Section 3507 of the Paperwork Reduction Act of 1955, 44 U.S.C. 35, as amended.

Dated: August 3, 1999.

**David S. Cristy,**

*Director, Investment Strategies, Policy, and Management.*

#### Notice of Submission of Proposed Information Collection to OMB

*Title of Proposal:* HMDA Loan/Application Register.